JP2006516576A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006516576A5 JP2006516576A5 JP2006501561A JP2006501561A JP2006516576A5 JP 2006516576 A5 JP2006516576 A5 JP 2006516576A5 JP 2006501561 A JP2006501561 A JP 2006501561A JP 2006501561 A JP2006501561 A JP 2006501561A JP 2006516576 A5 JP2006516576 A5 JP 2006516576A5
- Authority
- JP
- Japan
- Prior art keywords
- carbon atoms
- formula
- pharmaceutically acceptable
- compound
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000004432 carbon atom Chemical group C* 0.000 claims 58
- 150000003839 salts Chemical class 0.000 claims 39
- 150000001875 compounds Chemical class 0.000 claims 38
- 239000003814 drug Substances 0.000 claims 32
- 238000004519 manufacturing process Methods 0.000 claims 32
- 125000000217 alkyl group Chemical group 0.000 claims 31
- 230000002265 prevention Effects 0.000 claims 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 19
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 16
- 125000001153 fluoro group Chemical group F* 0.000 claims 16
- 229910052739 hydrogen Inorganic materials 0.000 claims 16
- 208000035475 disorder Diseases 0.000 claims 15
- 239000001257 hydrogen Substances 0.000 claims 11
- 125000003545 alkoxy group Chemical group 0.000 claims 10
- 229910052794 bromium Inorganic materials 0.000 claims 10
- 229910052801 chlorine Inorganic materials 0.000 claims 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims 9
- 229910052731 fluorine Inorganic materials 0.000 claims 9
- -1 (2,6-dichlorophenyl) (4-methyl-1H-imidazol-2-yl) amine Chemical class 0.000 claims 8
- 210000003169 central nervous system Anatomy 0.000 claims 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
- 230000004064 dysfunction Effects 0.000 claims 7
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims 6
- 239000004480 active ingredient Substances 0.000 claims 6
- 230000001154 acute effect Effects 0.000 claims 6
- 229910052740 iodine Inorganic materials 0.000 claims 6
- 210000000056 organ Anatomy 0.000 claims 6
- 230000002093 peripheral effect Effects 0.000 claims 6
- 208000023504 respiratory system disease Diseases 0.000 claims 6
- 238000001356 surgical procedure Methods 0.000 claims 6
- 230000006378 damage Effects 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 125000001054 5 membered carbocyclic group Chemical group 0.000 claims 4
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims 4
- 125000001960 7 membered carbocyclic group Chemical group 0.000 claims 4
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 4
- 208000033626 Renal failure acute Diseases 0.000 claims 4
- 206010041235 Snoring Diseases 0.000 claims 4
- 201000011040 acute kidney failure Diseases 0.000 claims 4
- 208000012998 acute renal failure Diseases 0.000 claims 4
- 230000001684 chronic effect Effects 0.000 claims 4
- 208000020832 chronic kidney disease Diseases 0.000 claims 4
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 230000000968 intestinal effect Effects 0.000 claims 4
- 201000002859 sleep apnea Diseases 0.000 claims 4
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 claims 3
- 125000003627 8 membered carbocyclic group Chemical group 0.000 claims 3
- 206010001497 Agitation Diseases 0.000 claims 3
- 206010002869 Anxiety symptoms Diseases 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 3
- 206010010904 Convulsion Diseases 0.000 claims 3
- 208000020401 Depressive disease Diseases 0.000 claims 3
- 206010048554 Endothelial dysfunction Diseases 0.000 claims 3
- 208000028017 Psychotic disease Diseases 0.000 claims 3
- 208000007536 Thrombosis Diseases 0.000 claims 3
- 208000027418 Wounds and injury Diseases 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 210000000013 bile duct Anatomy 0.000 claims 3
- 230000004663 cell proliferation Effects 0.000 claims 3
- 230000009693 chronic damage Effects 0.000 claims 3
- 230000036461 convulsion Effects 0.000 claims 3
- 244000078703 ectoparasite Species 0.000 claims 3
- 230000008694 endothelial dysfunction Effects 0.000 claims 3
- 206010015037 epilepsy Diseases 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 208000014674 injury Diseases 0.000 claims 3
- 208000028867 ischemia Diseases 0.000 claims 3
- 230000000302 ischemic effect Effects 0.000 claims 3
- 208000017169 kidney disease Diseases 0.000 claims 3
- 201000004792 malaria Diseases 0.000 claims 3
- 210000001428 peripheral nervous system Anatomy 0.000 claims 3
- 238000004321 preservation Methods 0.000 claims 3
- 230000010410 reperfusion Effects 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 208000007530 Essential hypertension Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 206010038687 Respiratory distress Diseases 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 208000015114 central nervous system disease Diseases 0.000 claims 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000008177 pharmaceutical agent Substances 0.000 claims 2
- 230000000241 respiratory effect Effects 0.000 claims 2
- 206010040560 shock Diseases 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 230000002485 urinary effect Effects 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 206010061481 Renal injury Diseases 0.000 claims 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims 1
- 238000006359 acetalization reaction Methods 0.000 claims 1
- 125000002777 acetyl group Chemical class [H]C([H])([H])C(*)=O 0.000 claims 1
- 230000009692 acute damage Effects 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 150000001540 azides Chemical class 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 125000004663 dialkyl amino group Chemical group 0.000 claims 1
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 239000007943 implant Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000005907 ketalization reaction Methods 0.000 claims 1
- 230000037356 lipid metabolism Effects 0.000 claims 1
- 230000029058 respiratory gaseous exchange Effects 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 0 *C(*)C(*)(ON)ON Chemical compound *C(*)C(*)(ON)ON 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10304374A DE10304374A1 (de) | 2003-02-04 | 2003-02-04 | Neue substituierte 2-Aminoimidazole, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| PCT/EP2004/000394 WO2004069806A2 (de) | 2003-02-04 | 2004-01-20 | Substituierte 2-aminoimidazole, verfahren zu ihrer herstellung, ihre verwendung als medikament oder diagnostikum sowie sie enthaltendes medikament |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010196422A Division JP2011016825A (ja) | 2003-02-04 | 2010-09-02 | 新規な置換された２−アミノイミダゾール、その製造方法、その医薬または診断薬としての使用、および、その化合物を含有する医薬品 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006516576A JP2006516576A (ja) | 2006-07-06 |
| JP2006516576A5 true JP2006516576A5 (https=) | 2007-03-01 |
| JP4630269B2 JP4630269B2 (ja) | 2011-02-09 |
Family
ID=32667986
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006501561A Expired - Fee Related JP4630269B2 (ja) | 2003-02-04 | 2004-01-20 | 新規な置換された２−アミノイミダゾール、その製造方法、その医薬または診断薬としての使用、および、その化合物を含有する医薬品 |
| JP2010196422A Abandoned JP2011016825A (ja) | 2003-02-04 | 2010-09-02 | 新規な置換された２−アミノイミダゾール、その製造方法、その医薬または診断薬としての使用、および、その化合物を含有する医薬品 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010196422A Abandoned JP2011016825A (ja) | 2003-02-04 | 2010-09-02 | 新規な置換された２−アミノイミダゾール、その製造方法、その医薬または診断薬としての使用、および、その化合物を含有する医薬品 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US7442717B2 (https=) |
| EP (2) | EP1592669B1 (https=) |
| JP (2) | JP4630269B2 (https=) |
| AR (1) | AR049671A1 (https=) |
| AT (1) | ATE375982T1 (https=) |
| AU (1) | AU2004208870A1 (https=) |
| BR (1) | BRPI0407212A (https=) |
| CA (1) | CA2514028A1 (https=) |
| DE (3) | DE10304374A1 (https=) |
| MX (1) | MXPA05007968A (https=) |
| PE (1) | PE20040943A1 (https=) |
| TW (1) | TW200508206A (https=) |
| WO (1) | WO2004069806A2 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050054705A1 (en) * | 2003-02-04 | 2005-03-10 | Aventis Pharma Deutschland Gmbh | N-substituted (benzoimidazol-2-yl) phenylamines, process for their preparation, their use as medicament or diagnostic aid, and medicament comprising them |
| WO2005107470A2 (en) * | 2004-04-29 | 2005-11-17 | University Of Florida Research Foundation, Inc. | Use of carbonic anhydrase inhibitors for insect control and malaria treatment |
| US7592362B2 (en) | 2006-01-19 | 2009-09-22 | Pfizer Limited | Substituted imidazoles |
| US20120088737A2 (en) * | 2009-10-02 | 2012-04-12 | Ajinomoto Co., Inc | Novel acyl guanidine derivatives |
| ME03311B (me) | 2014-07-25 | 2019-10-20 | Taisho Pharmaceutical Co Ltd | Fenil teтrahidroizokvinolinsko jedinjenje supsтituisano heteroarilom |
| CN109422695B (zh) * | 2017-08-28 | 2022-03-18 | 扬子江药业集团有限公司 | 一种盐酸苯达莫司汀粗品的制备方法 |
| CN118619883B (zh) * | 2024-05-24 | 2025-11-11 | 河北圣泰材料股份有限公司 | 一种4,5-二氰基-2-三氟甲基咪唑锂的制备方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3459763A (en) | 1966-01-25 | 1969-08-05 | Geigy Chem Corp | Certain amino imidazole derivatives |
| US4275072A (en) * | 1978-08-16 | 1981-06-23 | Farmos Group, Ltd. | 2,6-Dichlorophenyl-substituted amino-imidazole derivatives and use as hypertensive agents |
| JPS5547663A (en) * | 1978-08-16 | 1980-04-04 | Farmos Oy | 2*66dichlorophenyl substituted aminoo imidazole derivative*its acid addition salt* their manufacture and therapy of mammal using them |
| US4868183A (en) * | 1986-07-21 | 1989-09-19 | Otsuka Pharmaceutical Factory, Inc. | N-pyrazinyl substituted P-aminophenols |
| GR900100380A (el) * | 1989-05-20 | 1991-10-10 | Fisons Plc | Μέ?οδος παρασκευής αντι-φλεγμονωδών παραγώγων αμινοφενόλης. |
| ES2160700T3 (es) * | 1994-01-24 | 2001-11-16 | Allergan Sales Inc | Derivados aromaticos de 2-amino-imidazol como agonistas del adrenorreceptor alfa-2a. |
| DE19633966A1 (de) * | 1996-08-22 | 1998-02-26 | Hoechst Ag | Phenylsubstituierte Alkenylcarbonsäure-guanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE19945302A1 (de) | 1999-09-22 | 2001-03-29 | Merck Patent Gmbh | Biphenylderivate als NHE-3-Inhibitoren |
| WO2001021160A2 (en) * | 1999-09-23 | 2001-03-29 | Axxima Pharmaceuticals Aktiengesellschaft | Carboxymide and aniline derivatives as selective inhibitors of pathogens |
| DE19960204A1 (de) * | 1999-12-14 | 2001-06-28 | Aventis Pharma Gmbh | Substituierte Norlbornylamino-Derivate, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| DE10015248A1 (de) | 2000-03-28 | 2001-10-04 | Merck Patent Gmbh | Bisamidino-Verbindungen als NHE-3 Inhibitoren |
| DE10019062A1 (de) | 2000-04-18 | 2001-10-25 | Merck Patent Gmbh | 2-Guanidino-4-aryl-chinazoline als NHE-3 Inhibitoren |
| DE10043667A1 (de) | 2000-09-05 | 2002-03-14 | Merck Patent Gmbh | 2-Guanidino-4-aryl-chinazoline |
| EP1578341A2 (en) * | 2000-10-11 | 2005-09-28 | Tularik Inc. | Modulation of ccr4 function |
| DE10060292A1 (de) * | 2000-12-05 | 2002-06-20 | Aventis Pharma Gmbh | Verwendung substituierter Benzimidazole zur Herstellung eines Medikaments zur Behandlung von Krankheiten, welche durch Inhibierung des Na+/H+-Austauschers beeinflusst werden können und sie enthaltendes Medikament |
| US20030187045A1 (en) * | 2001-12-21 | 2003-10-02 | Uwe Heinelt | Substituted imidazolidines, process for their preparation, and their use as a medicament or diagnostic |
| US7049333B2 (en) * | 2002-06-04 | 2006-05-23 | Sanofi-Aventis Deutschland Gmbh | Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis |
-
2003
- 2003-02-04 DE DE10304374A patent/DE10304374A1/de not_active Withdrawn
-
2004
- 2004-01-20 JP JP2006501561A patent/JP4630269B2/ja not_active Expired - Fee Related
- 2004-01-20 AT AT04703371T patent/ATE375982T1/de not_active IP Right Cessation
- 2004-01-20 MX MXPA05007968A patent/MXPA05007968A/es unknown
- 2004-01-20 EP EP04703371A patent/EP1592669B1/de not_active Expired - Lifetime
- 2004-01-20 EP EP07014956A patent/EP1857445B1/de not_active Expired - Lifetime
- 2004-01-20 DE DE502004005260T patent/DE502004005260D1/de not_active Expired - Lifetime
- 2004-01-20 CA CA002514028A patent/CA2514028A1/en not_active Abandoned
- 2004-01-20 DE DE502004009771T patent/DE502004009771D1/de not_active Expired - Lifetime
- 2004-01-20 BR BR0407212-0A patent/BRPI0407212A/pt not_active IP Right Cessation
- 2004-01-20 WO PCT/EP2004/000394 patent/WO2004069806A2/de not_active Ceased
- 2004-01-20 AU AU2004208870A patent/AU2004208870A1/en not_active Abandoned
- 2004-01-28 PE PE2004000108A patent/PE20040943A1/es not_active Application Discontinuation
- 2004-02-02 TW TW093102254A patent/TW200508206A/zh unknown
- 2004-02-02 AR ARP040100314A patent/AR049671A1/es unknown
- 2004-02-03 US US10/771,185 patent/US7442717B2/en not_active Expired - Fee Related
-
2008
- 2008-07-14 US US12/172,380 patent/US20080275098A1/en not_active Abandoned
-
2010
- 2010-09-02 JP JP2010196422A patent/JP2011016825A/ja not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005519083A5 (https=) | ||
| RU2004106555A (ru) | Производные фенэтаноламина для лечения респираторных заболеваний | |
| RU2004133347A (ru) | Лекарственное средство для профилактики и/или лечения хронического отторжения | |
| JP2006511484A5 (https=) | ||
| JP2004526720A5 (https=) | ||
| RU2003120069A (ru) | Замещенные 2-анилино-бензимидазолы, их применение в качестве ингибиторов na+/h+-обмена, а также содержащее их лекарственное средство | |
| JP2011507896A5 (https=) | ||
| JP2004538259A5 (https=) | ||
| JP2009535307A5 (https=) | ||
| JP2001526218A5 (https=) | ||
| EA032028B1 (ru) | СТИМУЛЯТОРЫ рГЦ | |
| JP2007533686A5 (https=) | ||
| RU2009102278A (ru) | Модуляторы рецептора s1p для лечения рассеянного склероза | |
| JP2009528368A5 (https=) | ||
| JP2012525393A5 (https=) | ||
| TW200600492A (en) | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication | |
| JP2007520452A5 (https=) | ||
| RU2008152763A (ru) | Применение агонистов каннабиноидного рецептора в качестве индуцирующих гипотермию лекарственных средств для лечения ишемии | |
| JP2009526831A5 (https=) | ||
| JPH0920659A5 (https=) | ||
| RU2394031C2 (ru) | Соли четвертичного аммония в качестве антагонистов м3 | |
| JP2007515476A5 (https=) | ||
| JP2006516576A5 (https=) | ||
| JP2010513489A5 (https=) | ||
| JP2005533038A5 (https=) |